Inclusion Criteria:

1. locally advanced (>T1) or nodal positive (N+) histologically proven adenocarcinoma of
the esophagogastreal junction (AEG I-III) or the stomach without distant metastases
(M0) and without infiltration of adjacent structures and organs

2. no previous surgical resection

3. no previous cytostatic chemotherapy

4. Age > 18 years (female and male)

5. ECOG ≤ 2

6. surgical resectability

7. Exclusion of peritoneal carcinomatosis (if clinically suspected) via laparoscopy

8. Leucocytes > 3.000/µl

9. Platelets > 100.000/µl

10. Serum creatinin ≤ 1.5x of normal value, or Creatinin-Clearance > 50 ml/min

11. written informed consent.

12. Ejection fraction > 50% in echocardiography before start of therapy

Exclusion Criteria:

1. distant metastases or infiltration of adjacent structures or organs and all primarily
not resectable stages

2. relapse

3. Hypersensitivity against 5- Fluorouracil, Leucovorin, Oxaliplatin, Cisplatin.
Epirubicin and Docetaxel

4. Existence of contraindications against 5- Fluorouracil, Leucovorin, Oxaliplatin,
Cisplatin, Epirubicin or Docetaxel

5. Active CHD, Cardiomyopathy or cardiac insufficiency stage III-IV according to NYHA

6. malignant secondary disease, dated back < 5 years (exception: In-situ-carcinoma of
the cervix uteri, adequately treated skin basal cell carcinoma)

7. severe non-surgical accompanying disease or acute infection

8. peripheral polyneuropathy > NCI Grad II

9. severe liver dysfunction (AST/ALT>3,5xULN, AP>6xULN, Bilirubin>1,5xULN)

10. chronic inflammable gastro-intestinal disease

11. inclusion in another clinical trial

12. pregnancy or lactation